



## Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- [Upstream Bio, Inc.](#) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.

A live webcast of the presentation will be available under the [Events](#) tab on the Investors section of Upstream Bio's website on the day of the event. A replay will be available on the Company's website following the presentation.

### About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit [www.upstreambio.com](http://www.upstreambio.com).

### Investor and Media Contact:

Meggan Buckwell  
Director, Corporate Communications and Investor Relations  
[ir@upstreambio.com](mailto:ir@upstreambio.com)